Abstract
Success Rate of Helicobacter Pylori Therapy Among Adults 19 Years Old And Above Using Potassium Channel Acid Blocker (Vonoprazan) versus Proton Pump Inhibitors In Metropolitan Medical Center, A Comparative Study
Jervis T. Salvador, MD; Christine Marianne M. Sy, MD; Arlinking Ong-Go, M.D, FPCP, FPSG, FPSDE
Metropolitan Medical Center
Background: Helicobacter pylori colonizes the stomach in approximately 50% of the world’s population and 34% in the Philippines. It is associated with development of peptic ulcer disease and several malignancies. Standard triple therapy includes a proton pump inhibitor (PPI) and antibiotics. Recently, alternative medication like potassium channel acid blocker (PCAB) was introduced. Several international studies concluded that Vonoprazan-based regimen exhibited higher effectiveness and eradication rate comparedto PPI-based regimen without sacrificing safety.
Objectives: This study aimed to determine and compare the success rates of using PCAB (Vonoprazan) versus PPI in treating Helicobacter pylori positive patients.
Methodology: This is a retrospective cohort study conducted in Metropolitan Medical Center. H.pylori infected patients diagnosed by rapid urease test, histopathology and stool antigen test were studied. Patients were divided into PCAB and PPI group. Success rate was defined as a negative test for H. pylori 4 weeks or longer after the end of therapy or absence of symptoms after treatment
Results: Of the 116 patients (PCAB – 41, PPI – 75), there were more males compared to females, with mean ages between 50-60 years. The most common indication was abdominal pain. Though there is a trend of better H. pylori eradication rate and symptom relief in the PCAP group compared to PPI group, the differences were not statistically significant.
Conclusion: PCAB demonstrated a relatively higher H. pylori success rate and symptom relief in terms of age, sex and associated symptoms compared to PPI. Knowing the clinical and demographic data of concerned individuals can aid in treating H. pylori, thereby helping clinicians perform the proper management.
Keywords: Helicobacter pylori, Vonoprazan, Proton Pump Inhibitor
Important Dates to Remember
| JRRE Activities 2023-2024 |
Proposed Dates |
|---|---|
| Resumption of face-to-face Evidence-Based Medicine Workshop Venue to be announced once finalized. |
July 21, 2023 (Friday), 1-5pm |
| Monthly Critical Appraisal of Topics Conferences to be gaciliated by Research Coordinators per Institution | Monthly Critical Appraisal of Topics Conferences per Institution |
| CAT Plenary/Liver Con Dates: September 23, 2023 December 16, 2023 March 2024 (During the JAC) Resumption of face-to-face Quarterly Critical Appraisal of Topics facilitated by the JRRE |
2 Clinical scenarios and articles are to be sent to institutions each on August 2023, November 2023, and February 2024; |
| Hybrid Research Workshop 4 week asynchronous via Moodle, followed by a 1 day on-site Onsite Workshop Research Protocol Presentation for Level I GI Fellows-In-Training - Research Protocol Presentation: August 12, 2023 - Research Forums of the Tripartite Societies |
Week 1: July 15-21, 2023 Week 2: July 22-28, 2023 Week 3: July 29-August 4, 2023 Week 4: August 5-11, 2023 |
| Research Manuscript Workshop for level II GI Fellows-In-Training | January 6, 2024 |